EyePoint Pharmaceuticals (EYPT) Misses Q4 EPS by 55c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 EPS of ($1.16), $0.55 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.4 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS cuts KOSPI target by nearly 10% to reflect higher rates
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold